Creo Medical Group (LON:CREO) Insider Richard John Rees Purchases 6,250 Shares

Creo Medical Group PLC (LON:CREO) insider Richard John Rees acquired 6,250 shares of the stock in a transaction dated Wednesday, July 1st. The stock was acquired at an average cost of GBX 14 per share, with a total value of £875.

Creo Medical Group Stock Up 0.1%

Creo Medical Group stock traded up GBX 0.01 during trading on Monday, reaching GBX 14.57. The stock had a trading volume of 1,405,552 shares, compared to its average volume of 871,779. The company has a quick ratio of 2.19, a current ratio of 3.22 and a debt-to-equity ratio of 8.20. Creo Medical Group PLC has a 52-week low of GBX 9.52 and a 52-week high of GBX 18.50. The stock has a market cap of £70.81 million, a PE ratio of 14.57 and a beta of 1.62. The business has a 50 day moving average price of GBX 13.18 and a 200 day moving average price of GBX 12.90.

Creo Medical Group (LON:CREO) last issued its earnings results on Friday, May 22nd. The company reported GBX (0.04) EPS for the quarter. The firm had revenue of GBX 600 million for the quarter. Creo Medical Group had a return on equity of 9.56% and a net margin of 88.33%. On average, analysts predict that Creo Medical Group PLC will post -10.0800005 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Shore Capital Group restated a “house stock” rating and set a GBX 40 target price on shares of Creo Medical Group in a research note on Monday, June 29th.

Creo Medical Group Company Profile

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.